STRO

Sutro Biopharma, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.97
52-Week Range: $7.15 – $43.85
Market Cap: $254.52M
P/E (TTM): —
EPS (TTM): -17.28
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -36.08%
Gross Margin: -216.71%
Operating Margin: -301.73%
Profit Margin: 0.00%
Current Ratio: 3.32
Debt/Equity: —
Total Debt: $10.78M
Free Cash Flow: $-100.76M
Revenue Growth: -84.60%
Earnings Growth: —
Enterprise Value: $100.96M

STRO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$67.77M	$153.73M	$62.04M	$102.48M
Research & Development	$137.17M	$180.43M	$252.04M	$166.42M
Selling, General & Admin	$59.54M	$62.58M	$48.45M	$41.02M
Operating Expenses	$196.72M	$243.01M	$300.50M	$207.44M
Operating Income	-$128.94M	-$89.28M	-$238.45M	-$104.95M
EBITDA	-$107.67M	-$58.03M	-$186.81M	-$141.79M
Pretax Income	-$116.70M	-$88.60M	-$225.10M	-$191.18M
Income Tax	$2.50M	$18.19M	$2.36M	-$93.00K
Net Income	-$119.20M	-$106.79M	-$227.46M	-$191.09M
Diluted EPS	-23.50	-17.80	-29.40	-22.49
Diluted Shares	5.07M	6.02M	7.74M	8.50M

STRO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$47.25M	$69.27M	$190.30M	$58.13M
Receivables	$7.12M	$36.08M	$8.62M	$3.98M
Current Assets	$353.15M	$421.54M	$343.31M	$150.93M
Total Assets	$406.94M	$470.74M	$387.21M	$173.83M
Current Liabilities	$66.55M	$93.75M	$131.89M	$75.13M
Long-Term Debt	$3.77M	—	—	—
Total Debt	$50.43M	$33.63M	$23.15M	$15.67M
Total Liabilities	$189.90M	$321.09M	$342.61M	$306.28M
Retained Earnings	-$452.62M	-$559.41M	-$786.87M	-$977.96M
Shareholders' Equity	$217.05M	$149.65M	$44.60M	-$132.45M
Working Capital	$286.61M	$327.80M	$211.42M	$75.79M

STRO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$3.55M	-$111.62M	-$191.54M	-$177.23M
Capital Expenditure	-$7.86M	-$4.32M	-$3.10M	-$1.70M
Free Cash Flow	-$4.31M	-$115.93M	-$194.64M	-$178.93M
Depreciation & Amortisation	$5.69M	$6.82M	$7.22M	$7.32M
Stock-Based Compensation	$26.30M	$24.91M	$24.69M	$14.01M
Investing Cash Flow	-$35.02M	-$3.92M	$218.51M	$45.01M
Financing Cash Flow	$48.31M	$137.55M	$94.05M	$44.00K
Share Repurchases	$0.00	$0.00	—	—
Net Change in Cash	$16.84M	$22.01M	$121.02M	-$132.17M

STRO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$17.40M	$63.74M	$9.69M	$11.65M	$14.52M	$9.84M
Research & Development	$51.60M	$38.33M	$39.85M	$36.64M	$36.55M	$31.70M
Selling, General & Admin	$13.27M	$10.34M	$8.74M	$8.66M	$7.58M	$7.83M
Operating Expenses	$64.87M	$48.67M	$48.59M	$45.30M	$44.14M	$39.53M
Operating Income	-$47.47M	$15.08M	-$38.90M	-$33.66M	-$29.61M	-$29.69M
EBITDA	-$63.42M	$1.07M	-$44.55M	-$34.89M	-$26.74M	-$26.90M
Pretax Income	-$75.96M	-$11.52M	-$56.86M	-$46.84M	-$38.50M	-$38.53M
Income Tax	$7.00K	-$18.00K	$0.00	-$82.00K	-$15.00K	$1.00K
Net Income	-$75.97M	-$11.50M	-$56.86M	-$46.76M	-$38.48M	-$38.53M
Diluted EPS	-9.08	-1.40	-6.70	—	-2.94	-2.33
Diluted Shares	8.36M	8.46M	8.49M	—	13.08M	16.57M

STRO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$106.23M	$64.03M	$65.93M	$58.13M	$73.68M	$54.34M
Receivables	$13.56M	$8.00M	$3.92M	$3.98M	$12.48M	$5.80M
Current Assets	$287.41M	$231.63M	$182.11M	$150.93M	$220.97M	$175.65M
Total Assets	$321.43M	$262.36M	$209.66M	$173.83M	$241.99M	$194.46M
Current Liabilities	$133.05M	$74.25M	$71.89M	$75.13M	$70.81M	$52.90M
Total Debt	$21.40M	$19.59M	$17.66M	$15.67M	$13.63M	$10.78M
Total Liabilities	$347.24M	$294.47M	$296.93M	$306.28M	$308.88M	$297.78M
Retained Earnings	-$862.84M	-$874.34M	-$931.19M	-$977.96M	-$1.02B	-$1.05B
Shareholders' Equity	-$25.81M	-$32.11M	-$87.27M	-$132.45M	-$66.89M	-$103.32M
Working Capital	$154.36M	$157.38M	$110.22M	$75.79M	$150.16M	$122.75M

STRO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$67.88M	-$44.72M	-$38.19M	-$26.43M	-$42.26M	-$38.29M
Capital Expenditure	-$1.17M	-$86.00K	-$251.00K	-$184.00K	-$11.00K	—
Free Cash Flow	-$69.06M	-$44.81M	-$38.44M	-$26.62M	-$42.27M	-$38.29M
Depreciation & Amortisation	$1.90M	$1.90M	$1.90M	$1.62M	$1.28M	$1.26M
Stock-Based Compensation	$5.54M	$5.26M	$1.55M	$1.66M	$1.56M	$2.01M
Investing Cash Flow	-$16.26M	$2.58M	$39.99M	$18.70M	-$45.26M	$19.36M
Financing Cash Flow	$66.00K	-$60.00K	$102.00K	-$64.00K	$103.08M	-$418.00K
Net Change in Cash	-$84.08M	-$42.20M	$1.90M	-$7.80M	$15.55M	-$19.35M

Market Snapshot

About

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapies. The company uses its proprietary cell-free protein synthesis platform to create antibody drug conjugates (ADCs) and other targeted oncology treatments. Sutro is advancing multiple product candidates through clinical trials for various cancer types.